Research Grade Anti-Human MET/c-Met/HGFR (MvDN30) (HY196176)

데이터시트 제품 공유 정보 복사

가격(USD): $

사양:

100ug
1mg

수량:

문의하기

개요
이미지
참고 문헌
데이터시트

개요

카탈로그 번호	HY196176
설명	Anti-Human MET/c-Met/HGFR (MvDN30) (HY196176) is a research-grade recombinant antibody targeting Tyrosine-protein kinase Met. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
종 반응성	Human
응용 분야	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
숙주 종	Human
이소타입	IgG
클론 ID	MvDN30
발현 시스템	Mammalian Cells
클론성	Monoclonal
타겟	Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET
내독소 수준	Please contact the lab for this information.
순도	>95% purity as determined by SDS-PAGE.
정제	Protein A/G purified from cell culture supernatant.
등록번호	P08581
형태	Liquid
저장 완충액	0.01M PBS, pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.
안정성 및 저장	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
대체 이름	MvDN30
배경	Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).
참고사항	For research use only. Not suitable for clinical or therapeutic use.